Pear Therapeutics, Inc. [Rocket]

Overview

Pear Therapeutics, Inc.

Add to portfolio

Recent News + Filings (All items)

Date Filed	Type	Description
05/02/2023	25-NSE	Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
03/31/2023	10-K	Annual Report for the period ended December 31, 2022
03/17/2023	8-K	Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
02/24/2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/14/2023	SC 13G/A	SB Global Advisers Ltd reports a 8.6% stake in Pear Therapeutics, Inc.
02/09/2023	S-8	Form S-8 - Securities to be offered to employees in employee benefit plans:
01/24/2023	4	O'Brien Ronan (GC, CCO & Secretary) has filed a Form 4 on Pear Therapeutics, Inc.

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19
Revenues	12.7	4.2	28.2	32.6
Revenue growth	201.7%	-85.1%	-13.3%
Cost of goods sold	8.2	5.2	1.7	1.0
Gross profit	4.5	-1.0	26.5	31.6
Gross margin	35.5%	-24.4%	93.9%	96.9%
Selling, general and administrative	79.6	67.6	56.2	27.5
Research and development	48.3	37.0		35.7
EBITA	-122.7	-105.1	-77.6	-31.6
EBITA margin	-966.8%	-2498.1%	-275.0%	-97.1%
Amortization of intangibles	0.6	0.6
EBIT	-123.4	-105.7	-77.6	-31.6
EBIT margin	-971.7%	-2511.5%	-275.0%	-97.1%
Pre-tax income	-75.5	-65.1	-97.0	-9.3
Income taxes	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%
Net income	-75.5	-65.1	-108.1	-9.3
Net margin	-594.7%	-1548.1%	-382.8%	-28.7%

Diluted EPS	($0.54)	($0.57)	($1.21)	($0.63)
Shares outstanding (diluted)	138.7	113.3	89.2	14.8

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.